First, due to the impact of the financial crisis, international buyers are tightly funded, purchasing power is declining or the purchase cycle is prolonged, which not only affects the sales volume of China's APIs, but also increases the operating risks of exporting companies.
Second, the skyrocketing price has increased the fear and wait-and-see of international buyers, which has affected the steady development of the drug market.
Third, the price increase of some APIs is relatively large, causing the impulse of enterprises to expand production capacity, which has aggravated the contradiction of oversupply in the market.
Fourth, the currency depreciation of major export destination countries and competitor countries has reduced the price competitiveness of Chinese APIs and increased the difficulty of exports. Fifth, the financial crisis has intensified international trade protectionism and further worsened some of China's export market environment.